The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Open accessAbstract
Disease overview: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. Diagnosis: CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR‐ABL1 fusion oncogene, which in turn translates into a BCR‐ABL1 oncoprotein. Frontline therapy: Four tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, dasatinib, and bosutinib are approved by the United States Food and Drug Administration for first‐line treatment of patients with newly diagnosed CML in chronic phase (CML‐CP). Clinical trials with second generation TKIs reported significantly deeper and faster responses; this has not translated into improved long‐term survival, because of the availability of effective salvage therapies. Salvage therapy: For patients who fail frontline therapy, second‐line options include second and third generation TKIs. Second and third generation TKIs, although potent and selective, exhibit unique pharmacological profiles and response patterns relative to different patient and disease characteristics, such as patients’ comorbidities, disease stage, and BCR‐ABL1 mutational status. Patients who develop the T315I “gatekeeper” mutation display resistance to all currently available TKIs except ponatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML‐CP who have failed at least 2 TKIs, and for all patients in CML advanced phases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationOverriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationNilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Self-citationDasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Self-citationMahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609324 · Cited by 1,285
Self-citationO'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Prognostic discrimination in "good-risk" chronic granulocytic leukemia
Sokal, J., Cox, E., Baccarani, M., Tura, S., Gomez, G., Robertson, J., Tso, C., Braun, T., Clarkson, B., & Cervantes, F. (1984) · Blood · doi:10.1182/blood.v63.4.789.789 · Cited by 1,214
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Self-citationO'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8899 · Cited by 947
Self-citationMarin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3087 · Cited by 909
Hochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P. D., Etienne, G., Dorlhiac-Llacer, P. E., Clark, R. E., et al. (2016) · Leukemia · doi:10.1038/leu.2016.5 · Cited by 839
Self-citationHasford, J., Pfirrmann, M., Hehlmann, R., Allan, N. C., Baccarani, M., Kluin-Nelemans, J. C., Alimena, G., Steegmann, J. L., & Ansari, H. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.850 · Cited by 819
Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Yeung, D. T., Dang, P., Goyne, J. M., Slader, C., Filshie, R. J., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483750 · Cited by 710
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Tokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4187 · Cited by 700
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
Montani, D., Bergot, E., Günther, S., Savale, L., Bergeron, A., Bourdin, A., Bouvaist, H., Canuet, M., Pison, C., Macro, M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.079921 · Cited by 659
Noens, L., van Lierde, M.-A., De Bock, R., Verhoef, G., Zachée, P., Berneman, Z., Martiat, P., Mineur, P., Van Eygen, K., MacDonald, K., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196543 · Cited by 616
Deininger, M., O'Brien, S. G., Guilhot, F., Goldman, J. M., Hochhaus, A., Hughes, T. P., Radich, J. P., Hatfield, A. K., Mone, M., Filian, J., et al. (2009) · Blood · doi:10.1182/blood.v114.22.1126.1126 · Cited by 616
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., Marzinzik, A. L., Pelle, X., Donovan, J., Zhu, W., et al. (2017) · Nature · doi:10.1038/nature21702 · Cited by 614
Leukemia, E. I. C. M. (2013) · Blood · doi:10.1182/blood-2013-03-490003 · Cited by 592
Thomas, D. A. (2004) · Blood · doi:10.1182/blood-2003-08-2958 · Cited by 571
Ilaria, R. L., & Van Etten, R. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31704 · Cited by 488
Carlesso, N., Frank, D. A., & Griffin, J. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.811 · Cited by 483
Marin, D., Ibrahim, A. R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R. M., Clark, R. E., Apperley, J. F., Milojkovic, D., Bua, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6565 · Cited by 476
Silver, R. T., Woolf, S. H., Hehlmann, R., Appelbaum, F. R., Anderson, J., Bennett, C., Goldman, J. M., Guilhot, F., Kantarjian, H. M., Lichtin, A. E., et al. (1999) · PubMed · Cited by 463
Self-citationCortes, J. E., Kantarjian, H. M., Brümmendorf, T. H., Kim, D.-W., Turkina, A. G., Shen, Z.-X., Pasquini, R., Khoury, H. J., Arkin, S., Volkert, A., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355594 · Cited by 463
Self-citationConstitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai, K., Halpern, J., ten Hoeve, J., Rao, X., & Sawyers, C. L. (1996) · PubMed · Cited by 434
Gambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
Dominant negative MYC blocks transformation by ABL oncogenes
Sawyers, C. L., Callahan, W., & Witte, O. N. (1992) · Cell · doi:10.1016/0092-8674(92)90241-4 · Cited by 397
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
Raitano, A. B., Halpern, J. R., Hambuch, T. M., & Sawyers, C. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11746 · Cited by 394
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 392
Bending the Cost Curve in Cancer Care
Smith, T. J., & Hillner, B. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1013826 · Cited by 391
Ravandi, F., O'Brien, S., Thomas, D., Faderl, S., Jones, D., Garris, R., Dara, S., Jorgensen, J., Kebriaei, P., Champlin, R., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261586 · Cited by 348
Self-citationHehlmann, R., Lauseker, M., Jung-Munkwitz, S., Leitner, A., Müller, M. C., Pletsch, N., Proetel, U., Haferlach, C., Schlegelberger, B., Balleisen, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0598 · Cited by 323
Rea, D., Nicolini, F. E., Tulliez, M., Guilhot, F., Guilhot, J., Guerci-Bresler, A., Gardembas, M., Coiteux, V., Guillerm, G., Legros, L., et al. (2017) · Blood · doi:10.1182/blood-2016-09-742205 · Cited by 317
Schoch, C., Schnittger, S., Bursch, S., Gerstner, D., Hochhaus, A., Berger, U., Hehlmann, R., Hiddemann, W., & Haferlach, T. (2002) · Leukemia · doi:10.1038/sj.leu.2402329 · Cited by 314
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Holyoake, T. L., & Vetrie, D. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 314
Hughes, T., Saglio, G., Branford, S., Soverini, S., Kim, D.-W., Müller, M. C., Martinelli, G., Cortes, J., Beppu, L., Gottardi, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8230 · Cited by 306
Huang, X., Cortes, J., & Kantarjian, H. (2012) · Cancer · doi:10.1002/cncr.26679 · Cited by 300
Self-citationAichberger, K. J., Herndlhofer, S., Schernthaner, G., Schillinger, M., Mitterbauer‐Hohendanner, G., Sillaber, C., & Valent, P. (2011) · American Journal of Hematology · doi:10.1002/ajh.22037 · Cited by 296
Cortes, J., Jabbour, E., Kantarjian, H., Yin, C. C., Shan, J., O'Brien, S., Garcia-Manero, G., Giles, F., Breeden, M., Reeves, N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080838 · Cited by 296
Self-citationMüller, M. C., Cortes, J. E., Kim, D.-W., Druker, B. J., Erben, P., Pasquini, R., Branford, S., Hughes, T. P., Radich, J. P., Ploughman, L., et al. (2009) · Blood · doi:10.1182/blood-2009-04-214221 · Cited by 290
Zhou, T., Commodore, L., Huang, W., Wang, Y., Thomas, M., Keats, J., Xu, Q., Rivera, V. M., Shakespeare, W. C., Clackson, T., et al. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01054.x · Cited by 287
Cancer Drugs in the United States: Justum Pretium—The Just Price
Kantarjian, H. M., Fojo, T., Mathisen, M., & Zwelling, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1845 · Cited by 284
Self-citationCortes, J. E., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D.-W., Pane, F., Pasquini, R., Goldberg, S. L., Kalaycio, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3724 · Cited by 284
Self-citationDarkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725060-00004 · Cited by 271
Carpenter, P. A., Snyder, D., Flowers, M. E. D., Sanders, J. E., Gooley, T. A., Martin, P. J., Appelbaum, F. R., & Radich, J. P. (2006) · Blood · doi:10.1182/blood-2006-04-019836 · Cited by 226
Giles, F. J., Mauro, M. J., Hong, F., Ortmann, C.-E., McNeill, C., Woodman, R. C., Hochhaus, A., le Coutre, P. D., & Saglio, G. (2013) · Leukemia · doi:10.1038/leu.2013.69 · Cited by 216
Kantarjian, H., Pasquini, R., Lévy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., Hughes, T., Bleickardt, E., Dejardin, D., Cortes, J., et al. (2009) · Cancer · doi:10.1002/cncr.24504 · Cited by 215
Self-citationTyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia
Quintás-Cardama, A., Han, X., Kantarjian, H., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-09-180604 · Cited by 207
Self-citationWang, W., Cortes, J. E., Tang, G., Khoury, J. D., Wang, S., Bueso-Ramos, C. E., DiGiuseppe, J. A., Chen, Z., Kantarjian, H. M., Medeiros, L. J., et al. (2016) · Blood · doi:10.1182/blood-2016-01-690230 · Cited by 198
Self-citationSimonsson, B., Gedde-Dahl, T., Markevärn, B., Remes, K., Stentoft, J., Almqvist, A., Björeman, M., Flogegård, M., Koskenvesa, P., Lindblom, A., et al. (2011) · Blood · doi:10.1182/blood-2011-02-336685 · Cited by 194
Apperley, J. F., Cortes, J. E., Kim, D.-W., Roy, L., Roboz, G. J., Rosti, G., Bullorsky, E. O., Abruzzese, E., Hochhaus, A., Heim, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3339 · Cited by 194
Shah, N. P., Rousselot, P., Schiffer, C., Rea, D., Cortes, J. E., Milone, J., Mohamed, H., Healey, D., Kantarjian, H., Hochhaus, A., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24423 · Cited by 181
Self-citationRadich, J. P., Kopecky, K. J., Appelbaum, F. R., Kamel-Reid, S., Stock, W., Malnassy, G., Paietta, E., Wadleigh, M., Larson, R. A., Emanuel, P., et al. (2012) · Blood · doi:10.1182/blood-2012-02-410688 · Cited by 174
Carter, B. Z., Mak, P. Y., Mu, H., Zhou, H., Mak, D. H., Schober, W., Leverson, J. D., Zhang, B., Bhatia, R., Huang, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1180 · Cited by 170
Self-citationRole of p21 RAS in p210 bcr-abl transformation of murine myeloid cells
Mandanas, R., Leibowitz, D., Gharehbaghi, K., Tauchi, T., Burgess, G., Miyazawa, K., Jayaram, H., & Boswell, H. (1993) · Blood · doi:10.1182/blood.v82.6.1838.1838 · Cited by 165
Jain, P., Kantarjian, H. M., Ghorab, A., Sasaki, K., Jabbour, E. J., Nogueras Gonzalez, G., Kanagal‐Shamanna, R., Issa, G. C., Garcia‐Manero, G., KC, D., et al. (2017) · Cancer · doi:10.1002/cncr.30864 · Cited by 160
Self-citationKantarjian, H., Schiffer, C., Jones, D., & Cortes, J. (2008) · Blood · doi:10.1182/blood-2007-09-110189 · Cited by 158
Self-citationGallipoli, P., Cook, A., Rhodes, S., Hopcroft, L., Wheadon, H., Whetton, A. D., Jørgensen, H. G., Bhatia, R., & Holyoake, T. L. (2014) · Blood · doi:10.1182/blood-2013-12-545640 · Cited by 158
Jabbour, E. J., Kantarjian, H. M., Jones, D. M., Shan, J., O'Brien, S. M., Reddy, N., Wierda, W. G., Faderl, S. H., Garcia‐Manero, G., Verstovšek, S., et al. (2008) · Blood · doi:10.1182/blood-2008-04-154344 · Cited by 155
Self-citationKantarjian, H. M., Cortes, J. E., Kim, D., Khoury, H. J., Brümmendorf, T. H., Porkka, K., Martinelli, G., Durrant, S., Leip, E. P., Kelly, V. M., et al. (2013) · Blood · doi:10.1182/blood-2013-07-513937 · Cited by 151
Self-citationBleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
Quintás‐Cardama, A., Kantarjian, H. M., Ravandi, F., O'Brien, S. M., Thomas, D. M., Vidal‐Senmache, G., Wierda, W. G., Kornblau, S. M., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24257 · Cited by 150
Self-citationJain, P., Kantarjian, H. M., Nazha, A., O'Brien, S. M., Jabbour, E. J., Romo, C. G., Pierce, S. A., Cárdenas-Turanzas, M., Verstovšek, S., Borthakur, G. M., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490128 · Cited by 134
Self-citationLee, S. J., Kukreja, M. K., Wang, T., Giralt, S. A., Szer, J., Arora, M., Woolfrey, A. E., Cervantes, F., Champlin, R. E., Gale, R. P., et al. (2008) · Blood · doi:10.1182/blood-2008-02-141689 · Cited by 133
Oehler, V. G., Gooley, T. A., Snyder, D., Johnston, L., Lin, A., Cummings, C. C., Chu, S., Bhatia, R., Forman, S. J., Negrin, R. S., et al. (2006) · Blood · doi:10.1182/blood-2006-06-031682 · Cited by 132
Padula, W. V., Larson, R. A., Dusetzina, S. B., Apperley, J. F., Hehlmann, R., Baccarani, M., Eigendorff, E., Guilhot, J., Guilhot, F., Hehlmann, R., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw003 · Cited by 130
Wang, J., Shen, Z., Saglio, G. N., Jin, J., Huang, H., Hu, Y., Du, X., Li, J., Meng, F., Zhu, H., et al. (2015) · Blood · doi:10.1182/blood-2014-09-601674 · Cited by 113
Schnekenburger, M., Grandjenette, C., Ghelfi, J., Karius, T., Foliguet, B., Dicato, M. A., & Diederich, M. F. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.10.013 · Cited by 107
le Coutre, P. D., Giles, F. J., Hochhaus, A., Apperley, J. F., Ossenkoppele, G. J., Blakesley, R. E., Shou, Y., Gallagher, N. J., Baccarani, M., Cortes, J. E., et al. (2011) · Leukemia · doi:10.1038/leu.2011.323 · Cited by 99
Self-citationNeelakantan, P., Gerrard, G., Lucas, C., Milojković, D., May, P. C., Wang, L., Paliompeis, C., Bua, M., Reid, A. G., Rezvani, K., et al. (2013) · Blood · doi:10.1182/blood-2012-11-466037 · Cited by 95
Tefferi, A., & Letendre, L. (2011) · American Journal of Hematology · doi:10.1002/ajh.22051 · Cited by 86
Jain, P., Kantarjian, H. M., Alattar, M. L., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00021-6 · Cited by 83
Self-citationChronic Myelogenous Leukemia, Version 1.2014
O'Brien, S. M., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., DeAngelo, D. J., Deininger, M. W., Devine, S. M., Fathi, A. T., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0157 · Cited by 83
Jabbour, E. J., Branford, S., Saglio, G. N., Jones, D. M., Cortes, J. E., & Kantarjian, H. M. (2010) · Cancer · doi:10.1002/cncr.25717 · Cited by 82
Self-citationTestoni, N., Marzocchi, G., Luatti, S., Amabile, M., Baldazzi, C., Stacchini, M., Nanni, M., Rege‐Cambrin, G., Giugliano, E., Giussani, U., et al. (2009) · Blood · doi:10.1182/blood-2009-07-229864 · Cited by 81
Jabbour, E. J., Cortes, J. E., Santos, F. P. D. S., Jones, D. M., O'Brien, S. M., Rondón, G., Popat, U., Giralt, S., Kebriaei, P., Jones, R. B., et al. (2010) · Blood · doi:10.1182/blood-2010-08-302679 · Cited by 80
Self-citationJabbour, E. J., Kantarjian, H. M., O'Brien, S. M., Shan, J., Quintás‐Cardama, A., Garcia‐Manero, G., Rios, M. B., & Cortes, J. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0693 · Cited by 78
Self-citationHjorth‐Hansen, H., Stentoft, J., Richter, J., Koskenvesa, P., Höglund, M., Dreimane, A., Porkka, K., Gedde‐Dahl, T., Gjertsen, B. T., Gruber, F., et al. (2016) · Leukemia · doi:10.1038/leu.2016.121 · Cited by 72
Ko, T. K., Chuah, C. T. H., Huang, J. W. J., Ng, K.-P., & Ong, S. T. (2014) · Oncotarget · doi:10.18632/oncotarget.1925 · Cited by 71
Kantarjian, H. M., Shan, J., Jones, D. M., O'Brien, S. M., Rios, M. B., Jabbour, E. J., & Cortes, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6999 · Cited by 68
Self-citationChronic myeloid leukemia: First‐line drug of choice
Jabbour, E. J. (2015) · American Journal of Hematology · doi:10.1002/ajh.24249 · Cited by 65
Self-citationJabbour, E. J., Cortes, J. E., Kantarjian, H. M., Giralt, S., Andersson, B. S., Giles, F. J., Shpall, E. J., Kebriaei, P., Champlin, R. E., & de Lima, M. (2007) · Cancer · doi:10.1002/cncr.22778 · Cited by 64
Self-citationOhanian, M. N., Kantarjian, H. M., Quintás‐Cardama, A., Jabbour, E. J., Abruzzo, L. V., Verstovšek, S., Borthakur, G. M., Ravandi, F., Garcia‐Manero, G., Champlin, R. E., et al. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.08.008 · Cited by 63
Self-citationQuintás‐Cardama, A., Cortes, J. E., O'Brien, S. M., Ravandi, F., Borthakur, G. M., Liu, D., Bleickardt, E. W., Chen, T., & Kantarjian, H. M. (2009) · Cancer · doi:10.1002/cncr.24325 · Cited by 62
Self-citationMahon, F., Richter, J., Guilhot, J., Hjorth‐Hansen, H., de Almeida, A. P., Janssen, J. J. W. M., Mayer, J., Porkka, K., Panayiotidis, P. G., Strömberg, U., et al. (2016) · Blood · doi:10.1182/blood.v128.22.787.787 · Cited by 62
Molecular monitoring in chronic myeloid leukemia
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23427 · Cited by 59
Self-citationHughes, T. P., Leber, B. F., Cervantes, F., Spector, N., Pasqüini, R., Clementino, N., Schwarer, A. P., Dorlhiac‐Llacer, P. E., Mahon, F., Réa, D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.247 · Cited by 44
Cortes, J. E., Souza, C. A. D., Ayala, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30167-3 · Cited by 42
Kantarjian, H. M., & Cortes, J. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9176 · Cited by 40
Self-citationNazha, A., Kantarjian, H. M., Jain, P., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.090282 · Cited by 35
Self-citationHughes, T. P., Goh, Y. T., Ottmann, O. G., Minami, H., Réa, D., Lang, F., Mauro, M. J., DeAngelo, D. J., Talpaz, M., Hochhaus, A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.625.625 · Cited by 34
Jabbour, E. J., Kantarjian, H. M., Ghanem, H., O'Brien, S. M., Quintás‐Cardama, A., Garcia‐Manero, G., Cardenas, M., & Cortes, J. E. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.12.005 · Cited by 23
Self-citationCortes, J. E., Hochhaus, A., Kantarjian, H. M., Guilhot, F., Kota, V. K., Hughes, T. P., Shelat, S. G., Li, L., & Jabbour, E. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.7051 · Cited by 23
Self-citationSaußele, S., Richter, J., Guilhot, J., Hjorth‐Hansen, H., Almeida, A. M., Janssen, J. J. W. M., Mayer, J., Koskenvesa, P., Panayiotidis, P. G., Olsson‐Strömberg, U., et al. (2017) · University of Southern Denmark Research Portal (University of Southern Denmark) · Cited by 15
Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).
Kantarjian, H. M., Pinilla-Ibarz, J. A., le Coutre, P. D., PAQUETTE, R. L., Chuah, C. T. H., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., Baccarani, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.7012 · Cited by 9
Self-citationMonitoring and defining early response: Where to draw the line?
Branford, S. (2016) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2016.10.006 · Cited by 6
Naqvi, K., Cortes, J. E., Skinner, J. A., Jabbour, E. J., Pemmaraju, N., Bose, P., Thompson, P. A., Borthakur, G. M., Estrov, Z. E., & Kantarjian, H. M. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.1611.1611 · Cited by 2
Self-citation
Cited by
Tefferi, A., & Barbui, T. (2020) · American Journal of Hematology · doi:10.1002/ajh.26008 · Cited by 352
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Torti, S. V., & Torti, F. M. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100860 · Cited by 153
Soverini, S., Bavaro, L., De Benedittis, C., Martelli, M., Iurlo, A., Orofino, N., Sica, S., Sorà, F., Lunghi, F., Ciceri, F., et al. (2020) · Blood · doi:10.1182/blood.2019002969 · Cited by 100
Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib
Levêque, D., Becker, G., Bilger, K., & Natarajan-Amé, S. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00872-4 · Cited by 90
Metadata
- Authors
- Jabbour, E., & Kantarjian, H.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2018-02-07
- Volume
- 93
- Issue
- 3
- Pages
- 442-459
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2918115437
- Cited by
- 413
- References
- 105
- FWCI
- 30.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.